Nextpower Inc. R&D increased by 47.4% to $43.17M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 83.0%, from $23.59M to $43.17M. Over 3 years (FY 2023 to FY 2026), R&D shows an upward trend with a 77.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.65M | $3.58M | $3.98M | $4.32M | $4.98M | $8.34M | $5.63M | $7.15M | $12.90M | $13.09M | $16.52M | $19.19M | $20.09M | $23.59M | $21.56M | $26.89M | $29.29M | $43.17M |
| QoQ Change | — | -2.0% | +11.2% | +8.7% | +15.3% | +67.3% | -32.5% | +26.9% | +80.5% | +1.5% | +26.2% | +16.2% | +4.7% | +17.4% | -8.6% | +24.7% | +8.9% | +47.4% |
| YoY Change | — | — | — | — | +36.6% | +133.1% | +41.5% | +65.3% | +158.8% | +57.0% | +193.5% | +168.6% | +55.8% | +80.2% | +30.5% | +40.1% | +45.8% | +83.0% |
| Segment | Q1 '26 |
|---|---|
| Reportable Segment | $43.17M |
| Total | $43.17M |